Physician profile
Alberto Chavira
NPI 1508865759
$4,330.91
in general payments reported to CMS, 2019-2025
32 companies · $1,048 in 2025
The $1,048 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $453 · 2020: $249 · 2021: $608 · 2022: $483 · 2023: $949 · 2024: $542 · 2025: $1,048.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,538.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $503.59 | 2019-2024 | Farxiga, Brilinta |
| Novo Nordisk INC | $420.80 | 2020-2025 | Rybelsus, Ozempic |
| Biotronik INC. | $373.11 | 2020-2025 | Amvia Edge, Acticor 7 Vr-T Dx, Orsiro Mission |
| Bayer Healthcare Pharmaceuticals INC. | $346.53 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $339.06 | 2019-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $319.53 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $304.82 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $300.61 | 2021-2025 | Zepbound, Mounjaro |
| Esperion Therapeutics, INC. | $210.13 | 2021-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $181.08 | 2019-2025 | |
| Boston Scientific Corporation | $98.46 | 2019-2024 | Watchman Flx, Watchman Access System |
| Amgen INC. | $92.14 | 2021-2025 | Repatha, Repatha |
| Lexicon Pharmaceuticals, INC. | $87.23 | 2023-2024 | Inpefa |
| Pfizer INC. | $82.99 | 2020-2025 | |
| Inspire Medical Systems, INC. | $81.06 | 2025 | Inspire |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $60.28 | 2023-2024 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Strongbridge US INC. | $53.78 | 2020 | |
| Kiniksa Pharmaceuticals, LTD. | $47.57 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $45.72 | 2025 | Evkeeza |
| E.R. Squibb & Sons, L.L.C. | $44.89 | 2023-2024 | Eliquis |
| Sanofi-Aventis U.S. LLC | $44.47 | 2019 | |
| Akcea Therapeutics, INC. | $41.59 | 2019 | |
| Daiichi Sankyo INC. | $39.33 | 2025 | Injectafer |
| Baxter Healthcare | $32.24 | 2023-2024 | Hillrom - Cardiac Ambulatory Monitor |
| Xeris Pharmaceuticals, INC. | $32.04 | 2021 | |
| Philips North America LLC | $24.63 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Kestra Medical Technology Services, INC. | $23.29 | 2025 | Assure Wcd |
| Scpharmaceuticals INC. | $22.37 | 2023 | |
| Corcept Therapeutics | $20.79 | 2025 | Korlym |
| Ionis Pharmaceuticals, INC. | $20.49 | 2025 | Tryngolza |
| Abbott Laboratories | $19.09 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $17.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alberto Chavira listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.